A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Study Identifier
M23-893
CT.gov Identifier
NCT06024239
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Healthy Volunteer
  • Anxiety
  • Bipolar Disorder
    • Study Drug
  • ABBV-932
  • Placebo for ABBV-932
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * For healthy volunteer cohort: \-- Body mass index (BMI) is \>= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal. * For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD) * Participants with GAD or BPD (as confirmed by MINI) meet participant psychiatric history criteria described in the protocol.
    Exclusion Criteria:
    \- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.

    Protocol Summary

    The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).

    Study Locations

    Location
    Status
    Location
    Collaborative Neuroscience Research CNS /ID# 260270
    Los Alamitos, California, United States, 90720
    Status
    Not applicable
    Location
    Acpru /Id# 255945
    Grayslake, Illinois, United States, 60030
    Status
    Not applicable
    Location
    Hassman Research Institute Marlton Site /ID# 260271
    Marlton, New Jersey, United States, 08053
    Status
    Not applicable